期刊文献+

1例高龄弥漫大B细胞淋巴瘤的药学监护

下载PDF
导出
摘要 目的探讨临床药师对老年淋巴瘤肿瘤患者实施化学治疗的药学监护切入点。方法对1例胃弥漫大B细胞淋巴瘤高龄患者的治疗实施药学监护,包括协助制定化疗方案,参与患者病情变化时抗凝药物的调整,评估患者疼痛情况为患者的癌痛用药提供建议,监测并预防化疗药物不良反应,对患者进行用药教育等。结果通过临床药师的药学监护,实现高龄患者的个体化治疗,最大程度地减轻药物不良反应,保证用药安全有效。结论对于老年肿瘤患者,临床药师实施全程全方位的药学监护,可以充分发挥药师作用,建立临床药师在肿瘤多学科综合治疗中的地位。
出处 《医药导报》 CAS 2016年第8期846-848,共3页 Herald of Medicine
  • 相关文献

参考文献9

  • 1CASCIATODA.TERRITOMC.Manualofclinicaloncologyl[M].刘云鹏,李智,译.北京:中国协和医科大学出版社,2012:467-468.
  • 2National Comprehensive Cancer Network. Clinical practiceguidelines in oncology [ S ]. Non-Hodgkin' s Lymphomas. version 3,2012.
  • 3中国弥漫大B细胞淋巴瘤诊断与治疗指南(2013年版)[J].中华血液学杂志,2013,34(9):816-819. 被引量:239
  • 4PEYRADE F, JARDIN F, THIEBLEMONT C, et al. Attenu- ated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a muhicentre, single-arm, phase 2 trial [ J ]. Lancet Oncol,2011,12(5) :460-468.
  • 5CHISHOLM·BURNSMA.PharmacotherapyPrinciples&Practice[M].李涛,译.北京:人民军医出版社,2013:29.
  • 6PATE A J, BALTAZAR G A, LABANA S, et al. Systemic inflammatory response syndrome and platelet count I> 250 x 109 are associated with venous thromboembolic disease [ J ]. Int J Gen Med,2015(8) :37-40.
  • 7National Comprehensive Cancer Network. Clinical practice guidelines in oncology [ S ]. Venous Thromboembolic. version 2,2011.
  • 8LYMAN G H, BOHLKE K, KHORANA A A, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer : american society of clinical oncology clinical practice guideline update 2014 [ J ]. J Clin Oncol, 2015,33 ( 6 ) : 654 - 656.
  • 9孙嘉婧,曾勇,郑咏池.1例直肠癌患者术后伊立替康联合卡培他滨化学治疗方案的药学监护[J].中国药业,2014,23(8):62-63. 被引量:1

二级参考文献29

  • 1Korl AD, le Gessie S, Snijder S, et al. Primary extranodal non- Hodgkin' s lymphoma (NHL): the impact of alternative defini- tions tested in the Comprehensive Cancer Centre West popula- tion-based NHL registry. Ann Oncol, 2003, 14:131-139.
  • 2Li XQ, Li GD, Gao ZF, et al. The relative frequencies of lympho- ma subtypes in China: a nationwide study of 10002 cases by the Chinese Lymphoma Study Group. Ann Oncol, 2011, 22 Suppl 4: ivl41.
  • 3Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a stan- dard regimen (CHOP) with three intensive chemotherapy regi- mens for advanced non-Hodgkin' s lymphoma. N Engl J Med, 1993, 328:1002-1006.
  • 4Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med, 2005, 352:1197-1205.
  • 5Coiffier B, Thieblemont C, Van Den Neste E,et ah Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemother- apy in DLBCL patients: a study by the Grouped' Etudes des Lymphomes de 1' Adulte. Blood, 2010, 116:2040-2045.
  • 6Seki R, Ohshima K, Nagafuji K, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. Int J Hematol, 2010, 9 I: 258-266.
  • 7Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol, 2005, 23:5027-5033.
  • 8Habermama TM, Weller EA, Morrison VA, et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in old- er patients with diffuse large B-cell lymphoma. J Clin Oncol, 2006, 24:3121-3127.
  • 9Tilly H, Dreyling M. ESMO Guidelines Working Group. Diffuse large B-cell non-Hodgkin' s lymphoma: ESMO clinical recom- mendations for diagnosis, treatment and follow-up. Ann Oncol, 2008, Suppl 2:ii67-69.
  • 10NCCN Guidelines. Non-Hodgkin' s Lymphomas, version 2.2012.

共引文献238

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部